中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2015年
3期
271-274
,共4页
赵宪芝%庄洪卿%袁智勇%王境生%董洋%陈华明%李丰彤%宋勇春%王平
趙憲芝%莊洪卿%袁智勇%王境生%董洋%陳華明%李豐彤%宋勇春%王平
조헌지%장홍경%원지용%왕경생%동양%진화명%리봉동%송용춘%왕평
肾上腺,肿瘤转移/放射疗法%放射疗法,射波刀%治疗结果
腎上腺,腫瘤轉移/放射療法%放射療法,射波刀%治療結果
신상선,종류전이/방사요법%방사요법,사파도%치료결과
Adrenal,neoplasm metastases/radiotherapy%Radiotherapy,CyberKnife%Treatment outcome
目的 探讨SBRT技术治疗肾上腺转移癌的安全性和有效性.方法 回顾分析2006-2013年间应用射波刀治疗42例肾上腺转移癌患者的资料,以疗后1个月复查观察近期疗效.采用WHO的RECIST1.1标准进行评价,采用RTOG或EORTC放射损伤分级标准评价不良反应,采用Kaplan-Meier法计算生存率和LC率.结果 42例47个靶点纳入研究,其中14个病灶达CR,13个病灶达PR,总有效率为57%.1、2年样本数分别为25、19个靶点,1、2年LC,OS,PFS率分别为87%、60%,53%、41%,17%、8%.GTV<2.5 cm3、BED> 80 Gy、年龄>60岁均有助于提高局部PFS期.治疗后乏力、纳差、恶心、呕吐等胃肠道反应和骨髓抑制主要为1、2级反应,只有1例出现3级胃肠道反应.结论 SBRT技术治疗肾上腺转移癌不良反应轻且LC效果好.
目的 探討SBRT技術治療腎上腺轉移癌的安全性和有效性.方法 迴顧分析2006-2013年間應用射波刀治療42例腎上腺轉移癌患者的資料,以療後1箇月複查觀察近期療效.採用WHO的RECIST1.1標準進行評價,採用RTOG或EORTC放射損傷分級標準評價不良反應,採用Kaplan-Meier法計算生存率和LC率.結果 42例47箇靶點納入研究,其中14箇病竈達CR,13箇病竈達PR,總有效率為57%.1、2年樣本數分彆為25、19箇靶點,1、2年LC,OS,PFS率分彆為87%、60%,53%、41%,17%、8%.GTV<2.5 cm3、BED> 80 Gy、年齡>60歲均有助于提高跼部PFS期.治療後乏力、納差、噁心、嘔吐等胃腸道反應和骨髓抑製主要為1、2級反應,隻有1例齣現3級胃腸道反應.結論 SBRT技術治療腎上腺轉移癌不良反應輕且LC效果好.
목적 탐토SBRT기술치료신상선전이암적안전성화유효성.방법 회고분석2006-2013년간응용사파도치료42례신상선전이암환자적자료,이료후1개월복사관찰근기료효.채용WHO적RECIST1.1표준진행평개,채용RTOG혹EORTC방사손상분급표준평개불량반응,채용Kaplan-Meier법계산생존솔화LC솔.결과 42례47개파점납입연구,기중14개병조체CR,13개병조체PR,총유효솔위57%.1、2년양본수분별위25、19개파점,1、2년LC,OS,PFS솔분별위87%、60%,53%、41%,17%、8%.GTV<2.5 cm3、BED> 80 Gy、년령>60세균유조우제고국부PFS기.치료후핍력、납차、악심、구토등위장도반응화골수억제주요위1、2급반응,지유1례출현3급위장도반응.결론 SBRT기술치료신상선전이암불량반응경차LC효과호.
Objective To investigate the safety and efficacy of stereotactic body radiotherapy (SBRT) in the treatment of patients with adrenal metastases.Methods The clinical data of 42 patients with adrenal metastases who were treated with CyberKnife radiosurgery from 2006 to 2013 were retrospectively analyzed.Short-term outcomes at 1 month after treatment were evaluated.The evaluation was performed using RECIST 1.1 criteria by the World Health Organization.The adverse reactions were assessed using RTOG/EORTC radiation injury grading criteria,and the overall survival (OS) and local control (LC) rates were calculated using the Kaplan-Meier method.Results Among 47 targets in 42 patients,14 lesions showed a complete response,and 13 lesions showed a partial response,with an overall response rate of 57%.The sample sizes at 1 year and 2 years were 25 and 19,respectively.The 1-and 2-year LC rates were 87% and 60%,respectively.The 1-and 2-year OS rates were 53% and 41%,respectively,and the 1-and 2-year progression-free survival (PFS) rates were 17% and 8%,respectively.The PFS was substantially improved in patients with a gross target volume less than 2.5 cm3,a biologically equivalent dose higher than 80 Gy,and older than 60 years of age.The adverse reactions after treatment were mainly grade 1 or 2 gastrointestinal reactions including fatigue,anorexia,nausea,and vomit,and grade 1 or 2 bone marrow suppression.Only one patient showed grade 3 gastrointestinal reactions.Conclusion SBRT is a safe and effective method in the treatment of adrenal metastases with mild adverse reactions and good LC rates.